Adverse Event Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-small Cell Lung Cancer: An Updated Meta-analysis.
Susu ZhouNoriko KishiParissa AlerasoolNicholas C RohsPublished in: Targeted oncology (2024)
Epidermal growth factor receptor tyrosine kinase inhibitors were associated with a significantly increased risk of various types of AEs. Clinicians should be vigilant about the risks of these EGFR-TKI-related AEs, particularly for severe hepatotoxicity and interstitial lung disease, to facilitate early detection and proper management.
Keyphrases
- epidermal growth factor receptor
- interstitial lung disease
- tyrosine kinase
- advanced non small cell lung cancer
- chronic myeloid leukemia
- systemic sclerosis
- systematic review
- drug induced
- rheumatoid arthritis
- idiopathic pulmonary fibrosis
- meta analyses
- early onset
- palliative care
- human health
- adverse drug
- risk assessment
- emergency department
- small cell lung cancer